Lancet publishes results of Phase 3 programmes of Rinvoq in Ulcerative Colitis
Biotech

Lancet publishes results of Phase 3 programmes of Rinvoq in Ulcerative Colitis

Data from the three studies formed the basis of the company's application for approval by regulatory agencies

  • By IPP Bureau | May 27, 2022

AbbVie announced The Lancet published results from three pivotal Phase 3 clinical trials – U-ACHIEVE (induction), U-ACCOMPLISH and U-ACHIEVE (maintenance) – evaluating upadacitinib (Rinvoq) in patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to conventional or biologic therapy.

Data from the three studies formed the basis of the company's application for approval by regulatory agencies. The publication reports the efficacy and safety results of the two induction studies and a maintenance study evaluating clinical remission and endoscopic improvement with oral upadacitinib versus placebo over 8 weeks and 52 weeks, respectively.

The use of upadacitinib for ulcerative colitis is not approved in the European Union and its safety and efficacy remain under review by the global health authorities. 

About Ulcerative Colitis 

Ulcerative colitis is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) of the large intestine that causes continuous mucosal inflammation extending, to a variable extent, from the rectum to the more proximal colon. The hallmark signs and symptoms of ulcerative colitis include rectal bleeding, abdominal pain, bloody diarrhoea, tenesmus (a sense of pressure), urgency and faecal incontinence. The severity of symptoms and unpredictability of disease course can lead to substantial burden and often disability among those living with the disease. The disease course of ulcerative colitis varies between patients and can range from quiescent disease to chronic refractory disease, which in some cases can lead to surgery or complications, including cancer or death.

About the U-ACHIEVE Induction, U-ACCOMPLISH and U-ACHIEVE Maintenance Studies

The three Phase 3 studies are multicenter, randomized, double-blind, placebo-controlled studies to evaluate the efficacy and safety of upadacitinib 45 mg once daily as induction therapy, and upadacitinib 15 mg and 30 mg once daily as maintenance therapy in subjects with moderate to severe ulcerative colitis. Topline results of the U-ACHIEVE induction study were announced in December 2020, topline results of the second induction study, U-ACCOMPLISH, were announced in February 2021, and topline results of the U-ACHIEVE maintenance study were announced in June 2021.

Upcoming E-conference

Other Related stories

Startup

Digitization